Brensocatib is making waves in respiratory medicine. Following the full publication of its Phase 3 ASPEN trial in The New England Journal of Medicine in May 2025, this new oral treatment is being hailed as a breakthrough for people living with non-cystic fibrosis bronchiectasis (NCFBE). On 12 August 2025, the U.S FDA approved Brensocatib for … Continue reading Brensocatib: Is this breakthrough a Game-Changer for Bronchiectasis?